Page last updated: 2024-12-04

3,4-dihydrocoumarin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

melilotol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3,4-dihydrocoumarin : A chromanone that is the 3,4-dihydro derivative of coumarin. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID660
CHEMBL ID89306
CHEBI ID16151
SCHEMBL ID28795
MeSH IDM0086547

Synonyms (117)

Synonym
CHEMBL89306 ,
CHEBI:16151 ,
o-hydroxyhydrocinnamic acid delta-lactone
3,4-dihydro-2h-1-benzopyran-2-one
oxochroman
melilotic acid lactone
3,4-dihydro-2h-chromen-2-one
o-hydroxyhydrocinnamic acid lactone
einecs 204-354-9
3,4-dyhydrocoumarin
brn 0004584
nsc 10121
hydroxydihydrocinnamic acid lactone, o-
ccris 5803
dihydrobenzopyrone
ai3-03425
hsdb 4333
fema no. 2381
hydrocinnamic acid, o-hydroxy-, delta-lactone
hydrocinnamic acid, o-hydroxy-,lactone
nsc10121
coumarin,4-dihydro-
hydrocinnamic acid, .delta.-lactone
melilotine
chroman, 2-oxo-
nci-c55890
benzodihydropyrone
wln: t66 bovt & j
2h-1-benzopyran-2-one,4-dihydro-
nsc-10121
usaf do-12
benzopyranone, dihydro-
hydrocinnamic acid, o-hydroxy-, .delta.-lactone
2h-1-benzopyran-2-one, 3, 4-dihydro-
coumarin, 3,4-dihydro-
coumarin,3,4-dihydro
chroman-2-one
2h-1-benzopyran-2-one, 3,4-dihydro-
inchi=1/c9h8o2/c10-9-6-5-7-3-1-2-4-8(7)11-9/h1-4h,5-6h
NCGC00091491-01
1,2-benzodihydropyrone
melilotin
meliotine
dihydrocoumarin ,
119-84-6
melilotol
melilotic lactone
2-hydroxydihydrocinnamic acid lactone
2-chromanone
C02274
hydrocoumarin
3,4-dihydrocoumarin
o-hydroxydihydrocinnamic acid lactone
dihydrocoumarin, >=99%, fcc, fg
dihydrocoumarin, 99%
NCI60_000035
MLS002454372
smr000112325
bdbm50146070
AKOS000277415
3,4-dihydro-1-benzopyran-2-one
BMSE000412
D1223
3,4-dihydrochromen-2-one
STK801851
NCGC00091491-02
cas-119-84-6
tox21_302745
dtxcid00474
NCGC00256356-01
dtxsid2020474 ,
NCGC00259686-01
tox21_202137
HMS2268K22
S9379
nm5k1y1bt2 ,
5-17-10-00013 (beilstein handbook reference)
unii-nm5k1y1bt2
FT-0614320
BBL027621
SCHEMBL28795
o-hydroxy-hydrocinnamic acid-.delta.-lactone
dihydrocoumarin [fhfi]
melilotin [hsdb]
1,2-benzodihydropyrone [fcc]
dihydrocoumarin [inci]
2,3-dihydrocoumarin
dihydrocumarin
2-oxo-chroman
3,4 -dihydrocoumarin
3,4-dihydrocumarine
3,4-dihydrocoumarine
dihydrocoumarine
AC-34197
W-108495
mfcd00006881
HY-N1926
dihydrocoumarin, analytical standard
hydrocoumarin, 8ci
3,4-dihydro-coumarin
2-oxochroman
3,4-dihydroxycoumarin
dihydro-benzopyranone
fema 2381
melilotin (coumarin)
melilotin??
2-hydroxyhydrocinnamic lactone
CS-0018237
VS-08570
Q27098403
CCG-266187
D70234
dihydrocoumarin 100 microg/ml in acetonitrile
A892403
dihydrobenzenopyrone
EN300-49183
Z586249466

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" As both transient and prolonged exposure to environmental and dietary factors have the potential to lead to heritable alterations in epigenetic states and to modulate additional Sirtuin-dependent phenotypes, we examined the bioavailability and digestive stability of DHC using an in vivo rat model and in vitro digestive simulator."( Impacts on Sirtuin Function and Bioavailability of the Dietary Bioactive Compound Dihydrocoumarin.
Chapple, C; Ferruzzi, MG; Jacobi, JL; Janle, EM; Kirchmaier, AL; Laurentz, SM; Li, X; McCabe, GP; Menze, AK; Yang, B, 2016
)
0.43

Dosage Studied

ExcerptRelevanceReference
" A dose-response relation was seen when sensitized human subjects were challenged with dihydrocoumarin, alantroot oil and diethylmalleate."( Further studies of effects of vehicles and elicitation concentration in experimental contact sensitization testing in humans.
Maibach, HI; Marzulli, FN, 1980
)
0.26
" However, the mouse lung was identified as a major target organ in a chronic bioassay, with an oral gavage dosage of 200 mg/kg coumarin increasing the incidence of alveolar/bronchiolar adenomas and carcinomas."( Selective Clara cell injury in mouse lung following acute administration of coumarin.
Born, SL; Caudill, D; Fix, AS; Lehman-McKeeman, LD, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
chromanone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
coumarin metabolism (to melilotic acid)010

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency61.44150.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency68.93850.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency13.75500.000221.22318,912.5098AID1259243
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency34.55110.000657.913322,387.1992AID1259377
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency64.21230.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen nuclear receptor alphaHomo sapiens (human)Potency68.58960.000229.305416,493.5996AID1259244
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency0.19500.023723.228263.5986AID743222
thyroid stimulating hormone receptorHomo sapiens (human)Potency61.44150.001628.015177.1139AID1224843
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency74.97800.000627.21521,122.0200AID651741
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency68.58960.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency68.58960.001551.739315,848.9004AID1259244
Guanine nucleotide-binding protein GHomo sapiens (human)Potency5.62341.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NAD-dependent histone deacetylase SIR2Saccharomyces cerevisiae S288CIC50 (µMol)122.00008.80008.80008.8000AID204971
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NAD-dependent histone deacetylase SIR2Saccharomyces cerevisiae S288CInhibition0.15000.15000.67600.9400AID204972
NAD-dependent histone deacetylase SIR2Saccharomyces cerevisiae S288CMGC0.85000.49000.67000.8500AID204973
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID204973Sirtuin 2 inhibitory activity and was reported as minimum growth-stimulating concentration in Saccharomyces cerevisiae2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Inhibitors of Sir2: evaluation of splitomicin analogues.
AID204971In vitro inhibition of sirtuin 2 was evaluated using yeast whole cell lysates2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Inhibitors of Sir2: evaluation of splitomicin analogues.
AID204972In vitro inhibition of sirtuin 2 was evaluated using yeast whole cell lysates at 75 uM2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Inhibitors of Sir2: evaluation of splitomicin analogues.
AID235797Selectivity index was reported as the ratio of the MGC to IC50 value2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Inhibitors of Sir2: evaluation of splitomicin analogues.
AID342465Activity at human recombinant PON1 assessed as hydrolysis of lactone ring at 1 mM by Ellman's method2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Characterization of the PON1 active site using modeling simulation, in relation to PON1 lactonase activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (8.11)18.7374
1990's2 (5.41)18.2507
2000's9 (24.32)29.6817
2010's17 (45.95)24.3611
2020's6 (16.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.04 (24.57)
Research Supply Index3.64 (2.92)
Research Growth Index5.00 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other37 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]